Sitagliptin's effects on bone tissue and osseointegration in diabetic rats

Autor(es)

Gomez Bautista, Cristhian Reynaldo ^[1] ; dos Santos, Ingrid Valadares ^[1] ; Moraes, Renata Mendonca ^[1] ; Chiba, Fernando Yamamoto ^[2] ; Sumida, Doris Hissako ^[2] ; de Moraes, Michele Bianchi ^[3] ; Reis de Vasconcellos, Luana Marotta ^[1] ; Anbinder, Ana Lia ^[1]

Afiliação do(s) autor(es)

^[1] Sao Paulo State Univ Unesp, Dept Biosci & Oral Diag, Inst Sci & Technol, Av Engenheiro Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil

^[2] Sao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Rua Jose Bonifacio 1193, BR-16015050 Aracatuba, SP - Brazil

^[3] Sao Paulo State Univ Unesp, Inst Sci & Technol, Dept Diag & Surg, Av Engenheiro Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: ARCHIVES OF ORAL BIOLOGY; v. 102, p. 238-243, JUN 2019.
• Citações Web of Science: 0

Resumo

Objective: To investigate the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor used to treat type II diabetes, on bone tissue and on implant osseointegration in diabetic rats. Design: Thirty-two male rats were divided into four groups: 1) Diabetic animals (GD); 2) Diabetic animals that received sitagliptin (GDS); 3) Normoglycemic animals (GN); and 4) Normoglycemic animals that received sitagliptin (GNS). All animals received titanium implants in the right tibia. Sitagliptin or water were administered for 4 weeks. Glycemia, HOMA-IR, insulinemia, microtomographic parameters of the left tibia and implant bone area fraction occupancy (BAFO) of the right tibia were evaluated. Results: The model used to induce diabetes led to hyperglycemia. However, HOMA-IR results showed no insulin resistance, and insulinemia was lower in diabetic animals, demonstrating the development of type I diabetes. Sitagliptin administration did not influence glycemic control. The diabetic animals showed a lower BAFO and bone volume fraction, as well as a lower trabecular number and thickness, revealing the deleterious effect of diabetes on bone metabolism and osseointegration. Conclusion: In this model, sitagliptin administration did not reverse the negative effects of type I diabetes on bone, suggesting that sitagliptin has no direct action on bone tissue and has no protective bone action in de compensated diabetic animals. (AU)

• Processo FAPESP: 14/20973-6 - Efeitos da sitagliptina na osseointegração de implantes em ratos diabéticos e não diabéticos
• Beneficiário: Ingrid Valadares dos Santos
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 17/26461-5 - Estresse e periodontite: avaliação da inervação simpática no periodonto e da influência da noradrenalina em Porphyromonas gingivalis em Galleria mellonella
• Beneficiário: Renata Mendonça Moraes
• Modalidade de apoio: Bolsas no Brasil - Doutorado